Street Calls of the Week
PARIS - AB Science SA (Euronext:AB), a $4.37 billion market cap pharmaceutical company with a robust 7.65% dividend yield, announced Thursday initial Phase 1 data showing its experimental drug AB8939, when combined with venetoclax, achieved a 100% partial response rate in patients with refractory or relapsed acute myeloid leukemia (AML).
The early results, based on just three patients receiving third or fourth-line treatment, included one complete remission. These responses were observed after only the first cycle of treatment (14 days), with two patients having previously progressed on venetoclax combined with other chemotherapies.
According to the company, the combination therapy appears well-tolerated with low hematological toxicity, which could allow patients to receive multiple treatment cycles while maintaining quality of life.
AB8939 works through a dual mechanism of action, blocking leukemia cell proliferation through microtubule disruption while also targeting leukemia stem cells by inhibiting ALDH. The company believes this approach may help overcome the challenge of tumor recurrence in AML, a disease where 70% of patients relapse despite available treatments.
Nicholas J. Short, Associate Professor at MD Anderson Cancer Center, noted in the press release that "early data suggest that AB8939 could have significant activity in the highest risk subtypes of AML."
AB Science plans to complete the Phase 1 combination study and launch an expansion trial in approximately 15 AML patients. The company is discussing potential registrational study designs with regulatory authorities.
The company estimates the addressable market for treatments in relapsed or refractory AML at over €2 billion annually. AB8939’s intellectual property rights in AML are secured until 2036 through composition of matter patents, with potential extensions to 2041. According to InvestingPro data, AB Science maintains a GREAT financial health score of 3.46 and appears undervalued based on Fair Value analysis, suggesting potential upside for investors interested in this expanding market opportunity.
The information was disclosed in a company press release. For deeper insights into AB Science’s financial health and growth prospects, InvestingPro subscribers can access comprehensive analysis including 8 additional ProTips and detailed valuation metrics in the Pro Research Report, helping investors make more informed decisions about this promising pharmaceutical company.
In other recent news, AllianceBernstein Holding LP reported its financial results for the second quarter of 2025, highlighting a 7% increase in adjusted earnings per share to $0.76. The company also experienced a 2% rise in net revenues, reaching $844 million. These developments indicate positive financial performance for the firm. The company’s stock showed movement, although specific stock price details are not the focus here. Analyst firms have yet to provide upgrades or downgrades following these results. There have been no recent mergers or acquisitions reported for AllianceBernstein. These financial results are part of the latest developments concerning the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.